RT Journal Article
T1 Antiphospholipid Antibody Profile Stability Over Time: Prospective Results From the APS ACTION Clinical Database and Repository.
A1 Gkrouzman, Elena
A1 Sevim, Ecem
A1 Finik, Jackie
A1 Andrade, Danieli
A1 Pengo, Vittorio
A1 Sciascia, Savino
A1 Tektonidou, Maria G
A1 Ugarte, Amaia
A1 Chighizola, Cecilia B
A1 Belmont, H Michael
A1 Lopez-Pedrera, Chary
A1 Ji, Lanlan
A1 Fortin, Paul
A1 Efthymiou, Maria
A1 de Jesus, Guilherme Ramires
A1 Branch, D Ware
A1 Nalli, Cecilia
A1 Petri, Michelle
A1 Rodriguez, Esther
A1 Cervera, Ricard
A1 Knight, Jason S
A1 Atsumi, Tatsuya
A1 Willis, Rohan
A1 Bertolaccini, Maria Laura
A1 Cohen, Hannah
A1 Rand, Jacob
A1 Erkan, Doruk
K1 Anticardiolipin antibodies
K1 Antiphospholipid antibodies
K1 Antiphospholipid syndrome
AB The APS ACTION Registry studies long-term outcomes in persistently antiphospholipid antibody (aPL)-positive patients. Our primary objective was to determine whether clinically meaningful aPL profiles at baseline remain stable over time. Our secondary objectives were to determine (1) whether baseline characteristics differ between patients with stable and unstable aPL profiles, and (2) predictors of unstable aPL profiles over time. A clinically meaningful aPL profile was defined as positive lupus anticoagulant (LAC) test and/or anticardiolipin (aCL)/anti-β2 glycoprotein-I (anti-β2-GPI) IgG/M ≥ 40 U. Stable aPL profile was defined as a clinically meaningful aPL profile in at least two-thirds of follow-up measurements. Generalized linear mixed models with logit link were used for primary objective analysis. Of 472 patients with clinically meaningful aPL profile at baseline (median follow-up 5.1 yrs), 366/472 (78%) patients had stable aPL profiles over time, 54 (11%) unstable, and 52 (11%) inconclusive. Time did not significantly affect odds of maintaining a clinically meaningful aPL profile at follow-up in univariate (P = 0.906) and multivariable analysis (P = 0.790). Baseline triple aPL positivity decreased (OR 0.25, 95% CI 0.10-0.64, P = 0.004) and isolated LAC test positivity increased (OR 3.3, 95% CI 1.53-7.13, P = 0.002) the odds of an unstable aPL profile over time. Approximately 80% of our international cohort patients with clinically meaningful aPL profiles at baseline remain stable at a median follow-up of 5 years; triple aPL-positivity increase the odds of a stable aPL profile. These results will guide future validation studies of stored blood samples through APS ACTION Core Laboratories.
PB Journal of Rheumatology Publishing Co
SN 0315-162X
YR 2020
FD 2020-08-18
LK http://hdl.handle.net/10668/16708
UL http://hdl.handle.net/10668/16708
LA en
NO Gkrouzman E, Sevim E, Finik J, Andrade D, Pengo V, Sciascia S, et al. Antiphospholipid Antibody Profile Stability Over Time: Prospective Results From the APS ACTION Clinical Database and Repository. J Rheumatol. 2021 Apr;48(4):541-547
DS RISalud
RD Apr 12, 2025